FDA Removes Partial Clinical Hold on Gilead’s MDS and AML Magrolimab Studies

admin 3 years ago No Comments

This post was originally published on this site

“This is a significant milestone for Gilead and, more importantly, for patients diagnosed with these cancers,” Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences, said.

GILD shares are down 15% year-to-date.

Prev Article Next Article

Pork industry takes fight over California law to U.S. Supreme Court

admin October 10, 2022

Halliburton posts third-straight quarterly loss on shale slump

admin July 20, 2020

Wall Street Underestimates U.S. Consumers and Their Wallets

admin August 19, 2020

NASA’s Artemis moon launch delayed as storm expected in Florida

admin September 24, 2022

General Dynamics, American Rheinmetall chosen to compete to win potential $45 billion US Army vehicle contract

admin June 26, 2023

India’s economic outlook brightens amid global stimuli, despite potential threats

admin October 11, 2023

About The Author

admin

in your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

By signing up above you will receive the Daily Buzz Offers newsletter and 3rd party advertisements. Expect up to 5 messages per week from us. You can unsubscribe at any time at the bottom of any of our emails.

Related Posts

About The Author

admin